OraSure Technologies, Inc.  

(Public, NASDAQ:OSUR)   Watch this stock  
Find more results for OSUR
18.28
+0.27 (1.50%)
Feb 16 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 17.82 - 18.37
52 week 10.70 - 23.01
Open 17.89
Vol / Avg. 751,037.00/719,869.00
Mkt cap 1.11B
P/E 35.77
Div/yield     -
EPS 0.51
Shares 60.63M
Beta 1.42
Inst. own 98%
May 8, 2018
OraSure Technologies Inc Annual Shareholders Meeting - 10:00AM EDT - Add to calendar
May 1, 2018
Q1 2018 OraSure Technologies Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Feb 14, 2018
OraSure Technologies Inc at Leerink Partners Global Healthcare Conference
Feb 7, 2018
Q4 2017 OraSure Technologies Inc Earnings Call - Webcast
Feb 7, 2018
Q4 2017 OraSure Technologies Inc Earnings Release
Jan 11, 2018
OraSure Technologies Inc at JPMorgan Healthcare Conference - Webcast
Jan 4, 2018
OraSure Technologies, Inc. to Discuss the Organizational Changes and Updated Financial Guidance Conference Call - Webcast
Dec 1, 2017
OraSure Technologies, Inc. - Special Call
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '17) 2017
Net profit margin 14.06% 18.52%
Operating margin 19.53% 24.09%
EBITD margin - 20.44%
Return on average assets 10.15% 12.28%
Return on average equity 11.56% 13.94%
Employees 325 -
CDP Score - -

Address

150 WEBSTER ST
BETHLEHEM, PA 18015
United States - Map
+1-503-6416115 (Phone)
+1-610-8821830 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

OraSure Technologies, Inc. (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types. The Company operates in two segments: OSUR and DNAG. OSUR consists of the development, manufacture and sale of diagnostic products, specimen collection devices, and medical devices. DNAG or molecular collection systems business consists primarily of the development, manufacture and sale of oral fluid collection devices that are used to collect, stabilize, and store samples of genetic material for molecular testing. It also manufactures and sells medical devices used for the removal of benign skin lesions by cryosurgery or freezing. It sells over-the-counter (OTC) cryosurgical products to consumers in North America, Europe, Central and South America, and Australia.

Officers and directors

Stephen S. Tang Ph.D. Chairman of the Board, President, Chief Executive Officer
Age: 56
Bio & Compensation  - Reuters
Douglas A. Michels President, Chief Executive Officer, Director
Age: 60
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Ronald H. Spair Chief Financial Officer, Chief Operating Officer, Director
Age: 61
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Anthony Zezzo II Executive Vice President - Marketing and Sales
Age: 63
Bio & Compensation  - Reuters
Mark L. Kuna Senior Vice President - Finance, Controller, Assistant Secretary
Age: 54
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Michael Reed Ph.D. Senior Vice President - Research and Development, Chief Scientific Officer
Age: 48
Bio & Compensation  - Reuters
Jack E. Jerrett Senior Vice President, General Counsel, Secretary
Age: 58
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Mara Glickman Aspinall Director
Age: 54
Bio & Compensation  - Reuters
Aradhana Sarin Director
Age: 43
Bio & Compensation  - Reuters
Michael Celano Independent Director
Age: 58
Bio & Compensation  - Reuters